Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis

ABSTRACT Cancer metastasis is a major cause of cancer-related mortality. Strategies to reduce metastases are needed especially in lung cancer, the most common cause of cancer mortality. We previously reported increased ubiquitin-specific peptidase 18 (USP18) expression in lung and other cancers. Engineered reduction of USP18 expression repressed lung cancer growth and promoted apoptosis. This deubiquitinase (DUB) stabilized targeted proteins by removing the complex interferon-stimulated gene 15 (ISG15). This study explores if the loss of USP18 reduced lung cancer metastasis. USP18 knock-down in lung cancer cells was independently achieved using small hairpin RNAs (shRNAs) and small interfering RNAs (siRNAs). USP18 knock-down reduced lung cancer growth, wound-healing, migration, and invasion versus controls (P < .001) and markedly decreased murine lung cancer metastases (P < .001). Reverse Phase Protein Arrays (RPPAs) in shRNA knock-down lung cancer cells showed that 14-3-3ζ protein was regulated by loss of USP18. ISG15 complexed with 14-3-3ζ protein reducing its stability. Survival in lung adenocarcinomas (P < .0015) and other cancers was linked to elevated 14-3-3ζ expression as assessed by The Cancer Genome Atlas (TCGA). The findings were confirmed and extended using 14-3-3ζ immunohistochemical assays of human lung cancer arrays and syngeneic murine lung cancer metastasis models. A direct 14-3-3ζ role in controlling lung cancer metastasis came from engineered 14-3-3ζ knock-down in lung cancer cell lines and 14-3-3ζ rescue experiments that reversed migration and invasion inhibition. Findings presented here revealed that USP18 controlled metastasis by regulating 14-3-3ζ expression. These data provide a strong rationale for developing a USP18 inhibitor to combat metastases.

[1]  Xin Yu,et al.  Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis , 2020, Aging.

[2]  L. Cai,et al.  Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling , 2020, Frontiers in Oncology.

[3]  Jiaxing Wang,et al.  USP18 directly regulates Snail1 protein through ubiquitination pathway in colorectal cancer , 2020, Cancer Cell International.

[4]  Shuang Feng,et al.  USP18 deubiquitinates and stabilizes Twist1 to promote epithelial-mesenchymal transition in glioblastoma cells. , 2020, American journal of cancer research.

[5]  Huifen Chen,et al.  USP18 promotes cell proliferation and suppressed apoptosis in cervical cancer cells via activating AKT signaling pathway , 2020, BMC Cancer.

[6]  R. Chari,et al.  Structure of E3 ligase E6AP with a proteasome-binding site provided by substrate receptor hRpn10 , 2020, Nature Communications.

[7]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[8]  Victoria Hewett.  Progression , 2019, Making it as a Teacher.

[9]  Hyo Song Kim,et al.  Clinical analysis of patients with skeletal metastasis of lung cancer , 2019, BMC Cancer.

[10]  J. Doroshow,et al.  Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers , 2019, Clinical Cancer Research.

[11]  KL Pennington,et al.  The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein–protein interactions , 2018, Oncogene.

[12]  B. Sabloff,et al.  Staging Lung Cancer: Metastasis. , 2018, Radiologic clinics of North America.

[13]  Nobuhiro Nakamura,et al.  Ubiquitin System , 2018, International journal of molecular sciences.

[14]  E. Dmitrovsky,et al.  Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target. , 2018, Cancer research.

[15]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[16]  Stephen P. Jackson,et al.  Deubiquitylating enzymes and drug discovery: emerging opportunities , 2017, Nature Reviews Drug Discovery.

[17]  E. Dmitrovsky,et al.  Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer , 2017, Journal of the National Cancer Institute.

[18]  E. Dmitrovsky,et al.  Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer , 2017, Molecular Cancer Research.

[19]  K. Knobeloch,et al.  Structural basis of the specificity of USP18 toward ISG15 , 2017, Nature Structural &Molecular Biology.

[20]  Dong-er Zhang,et al.  Multiple functions of USP18 , 2016, Cell Death & Disease.

[21]  Yan-bin Zhao,et al.  14-3-3ζ/TGFβR1 promotes tumor metastasis in lung squamous cell carcinoma , 2016, Oncotarget.

[22]  W. Zhai,et al.  14-3-3ζ promotes lung cancer cell invasion by increasing the Snail protein expression through atypical protein kinase C (aPKC)/NF-κB signaling. , 2016, Experimental cell research.

[23]  W. Zhai,et al.  Loss of Par3 promotes lung adenocarcinoma metastasis through 14-3-3ζ protein , 2016, Oncotarget.

[24]  H. Popper.  Progression and metastasis of lung cancer , 2016, Cancer and Metastasis Reviews.

[25]  A. Adjei,et al.  New strategies to develop new medications for lung cancer and metastasis , 2015, Cancer and Metastasis Reviews.

[26]  Stephen R. Piccolo,et al.  Histone Deacetylase 6 (HDAC6) Promotes the Pro-survival Activity of 14-3-3ζ via Deacetylation of Lysines within the 14-3-3ζ Binding Pocket* , 2015, The Journal of Biological Chemistry.

[27]  Ivan Dikic,et al.  Ubiquitination in disease pathogenesis and treatment , 2014, Nature Medicine.

[28]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[29]  Jie Gu,et al.  The overexpression of 14‐3‐3ζ and Hsp27 promotes non–small cell lung cancer progression , 2014, Cancer.

[30]  E. Dmitrovsky,et al.  Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target , 2012, Molecular Cancer Therapeutics.

[31]  W. Zhang,et al.  Targeting 14-3-3zeta in cancer therapy , 2011, Cancer Gene Therapy.

[32]  C. Brancolini,et al.  Type I IFNs signaling and apoptosis resistance in glioblastoma cells , 2011, Apoptosis.

[33]  W. Hur,et al.  Silencing of 14-3-3ζ over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. , 2011, Cancer letters.

[34]  Dong-er Zhang,et al.  Interferon-stimulated gene 15 and the protein ISGylation system. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[35]  E. Dmitrovsky,et al.  Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. , 2010, Cancer research.

[36]  E. Dmitrovsky,et al.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. , 2010, The Journal of clinical investigation.

[37]  C. Brancolini,et al.  Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. , 2010, Cancer research.

[38]  David Komander,et al.  Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.

[39]  Hua Guo,et al.  14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. , 2009, Cancer research.

[40]  E. Choi.  Faculty Opinions recommendation of Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. , 2008 .

[41]  F. Khuri,et al.  Down-regulation of 14-3-3ζ suppresses anchorage-independent growth of lung cancer cells through anoikis activation , 2008, Proceedings of the National Academy of Sciences.

[42]  M. Niemantsverdriet,et al.  Cellular functions of 14-3-3ζ in apoptosis and cell adhesion emphasize its oncogenic character , 2007, Oncogene.

[43]  Ming Yan,et al.  Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. , 2007, Blood.

[44]  Dong-er Zhang,et al.  Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. , 2007, Biochemical and biophysical research communications.

[45]  G. Tzivion,et al.  14-3-3 proteins as potential oncogenes. , 2006, Seminars in cancer biology.

[46]  D. Bridges,et al.  14-3-3 Proteins: A Number of Functions for a Numbered Protein , 2005, Science's STKE.

[47]  Steven Gygi,et al.  Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Mhawech,et al.  14-3-3 proteins—an update , 2005, Cell Research.

[49]  Angel F. Lopez,et al.  The Dimeric Versus Monomeric Status of 14-3-3ζ Is Controlled by Phosphorylation of Ser58 at the Dimer Interface* , 2003, Journal of Biological Chemistry.

[50]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[51]  S. Zhang,et al.  Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis. , 2016, Cancer research.

[52]  W. Ha,et al.  The differential proteome profile of stomach cancer: identification of the biomarker candidates. , 2004, Oncology research.

[53]  S. Masters,et al.  14-3-3 proteins: structure, function, and regulation. , 2000, Annual review of pharmacology and toxicology.